Nerandomilast Slows Lung Function Decline, Reduces Mortality Risk in Autoimmune ILD SubgroupByPatrick CampbellJune 10th 2026
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhDByXenofon Baraliakos, MD, PhDJune 8th 2026
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-HeadByPhilip J. Mease, MDJune 8th 2026
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA StudyByXenofon Baraliakos, MD, PhDJune 6th 2026